Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
02 Mars 2024 - 12:00AM
Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage
biopharmaceutical company discovering and developing clinically
differentiated small molecule therapeutics targeting fundamental
biological pathways of cancer, today announced that on March 1,
2024, the Compensation Committee of Zentalis’ Board of Directors
granted non-qualified stock options to purchase an aggregate of
125,000 shares of the Company’s common stock to two newly hired
employees. The stock options were granted under the Zentalis
Pharmaceuticals, Inc. 2022 Employment Inducement Incentive Award
Plan (2022 Inducement Plan) as an inducement material to each such
individual’s entering into employment with Zentalis in accordance
with Nasdaq Listing Rule 5635(c)(4).
The 2022 Inducement Plan is used exclusively for the grant of
equity awards to individuals who were not previously employees of
Zentalis, or following a bona fide period of non-employment, as an
inducement material to each such individual’s entering into
employment with Zentalis, pursuant to Nasdaq Listing Rule
5635(c)(4).
The stock options have an exercise price of $15.28 per share,
which is equal to the closing price of Zentalis’ common stock on
The Nasdaq Global Market on the date of grant. The stock options
have a 10-year term and will vest over four years, with 25% of the
options vesting on the first anniversary of the vesting
commencement date and the remaining 75% of the options vesting in
equal monthly installments over the three years thereafter.
Vesting of the stock options is subject to the employee’s
continued service to Zentalis on each vesting date.
About Zentalis PharmaceuticalsZentalis®
Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company
discovering and developing clinically differentiated small molecule
therapeutics targeting fundamental biological pathways of cancers.
The Company’s lead product candidate, azenosertib (ZN-c3), is a
potentially first-in-class and best-in-class WEE1 inhibitor for
advanced solid tumors and hematologic malignancies. Azenosertib is
being evaluated as a monotherapy and in combination across multiple
clinical trials and has broad franchise potential. In clinical
trials, azenosertib has been well tolerated and has demonstrated
anti-tumor activity as a single agent across multiple tumor types
and in combination with several chemotherapy backbones. As part of
its azenosertib clinical development program, the Company is
exploring enrichment strategies targeting tumors of high genomic
instability, such as Cyclin E1 positive tumors, homologous
recombination deficient tumors and tumors with oncogenic driver
mutations. The Company is also leveraging its extensive experience
and capabilities across cancer biology and medicinal chemistry to
advance its research on protein degraders. Zentalis has operations
in both New York and San Diego.
For more information, please visit www.zentalis.com. Follow
Zentalis on Twitter at @ZentalisP and on LinkedIn at
www.linkedin.com/company/zentalis-pharmaceuticals.
Contact:
Carlo Tanzi, Ph.D.Kendall Investor
Relationsctanzi@kendallir.com
Zentalis Pharmaceuticals (NASDAQ:ZNTL)
Graphique Historique de l'Action
De Août 2024 à Sept 2024
Zentalis Pharmaceuticals (NASDAQ:ZNTL)
Graphique Historique de l'Action
De Sept 2023 à Sept 2024